David Lebwohl

2021

In 2021, David Lebwohl earned a total compensation of $4.3M as Executive Vice President, Chief Medical Officer at Intellia Therapeutics, a 105% increase compared to previous year.

Compensation breakdown

Bonus$269,480
Option Awards$2,792,916
Salary$458,300
Stock Awards$735,803
Other$9,060
Total$4,265,559

Lebwohl received $2.8M in option awards, accounting for 65% of the total pay in 2021.

Lebwohl also received $269.5K in bonus, $458.3K in salary, $735.8K in stock awards and $9.1K in other compensation.

Rankings

In 2021, David Lebwohl's compensation ranked 3,117th out of 12,415 executives tracked by ExecPay. In other words, Lebwohl earned more than 74.9% of executives.

ClassificationRankingPercentile
All
3,117
out of 12,415
75th
Division
Manufacturing
1,252
out of 5,505
77th
Major group
Chemicals And Allied Products
506
out of 2,375
79th
Industry group
Drugs
448
out of 2,096
79th
Industry
In Vitro and In Vivo Diagnostic Substances
8
out of 61
87th
Source: SEC filing on May 2, 2022.

Lebwohl's colleagues

We found four more compensation records of executives who worked with David Lebwohl at Intellia Therapeutics in 2021.

2021

James Basta

Intellia Therapeutics

General Counsel

2021

John Leonard

Intellia Therapeutics

Chief Executive Officer

2021

Laura Sepp-Lorenzino

Intellia Therapeutics

Chief Scientific Officer

2021

Glenn Goddard

Intellia Therapeutics

Chief Financial Officer

News

In-depth

You may also like